Nada, I beleive CC would be overkill, so am assuming PR. I sent Matt Pfeffer an email suggesting strategic value of issuing 2 seperate PR - one for each trial. I also know that a friend of mine suggested the same to him in a phone call. Of course, Matt would not commit or comment.
Although completing the trial is a virtual certainty, the market will appreciate one less variable in the risk equation plus officially starting the clock ticking to FDA submission. My guess is that if we haven't broken $4 by then, we will after announcing trials are complete.
